1. Home
  2. NTLA vs BXC Comparison

NTLA vs BXC Comparison

Compare NTLA & BXC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NTLA
  • BXC
  • Stock Information
  • Founded
  • NTLA 2014
  • BXC 2004
  • Country
  • NTLA United States
  • BXC United States
  • Employees
  • NTLA N/A
  • BXC 2000
  • Industry
  • NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • BXC Wholesale Distributors
  • Sector
  • NTLA Health Care
  • BXC Consumer Discretionary
  • Exchange
  • NTLA Nasdaq
  • BXC Nasdaq
  • Market Cap
  • NTLA 710.1M
  • BXC 546.7M
  • IPO Year
  • NTLA 2016
  • BXC 2004
  • Fundamental
  • Price
  • NTLA $6.87
  • BXC $66.79
  • Analyst Decision
  • NTLA Buy
  • BXC Strong Buy
  • Analyst Count
  • NTLA 20
  • BXC 5
  • Target Price
  • NTLA $38.40
  • BXC $115.40
  • AVG Volume (30 Days)
  • NTLA 5.0M
  • BXC 82.7K
  • Earning Date
  • NTLA 05-08-2025
  • BXC 07-29-2025
  • Dividend Yield
  • NTLA N/A
  • BXC N/A
  • EPS Growth
  • NTLA N/A
  • BXC N/A
  • EPS
  • NTLA N/A
  • BXC 4.53
  • Revenue
  • NTLA $45,569,000.00
  • BXC $2,935,514,000.00
  • Revenue This Year
  • NTLA N/A
  • BXC $3.40
  • Revenue Next Year
  • NTLA N/A
  • BXC $5.01
  • P/E Ratio
  • NTLA N/A
  • BXC $14.79
  • Revenue Growth
  • NTLA N/A
  • BXC N/A
  • 52 Week Low
  • NTLA $5.90
  • BXC $63.55
  • 52 Week High
  • NTLA $28.18
  • BXC $134.79
  • Technical
  • Relative Strength Index (RSI)
  • NTLA 38.33
  • BXC 44.14
  • Support Level
  • NTLA $8.93
  • BXC $64.91
  • Resistance Level
  • NTLA $9.79
  • BXC $68.71
  • Average True Range (ATR)
  • NTLA 0.58
  • BXC 2.24
  • MACD
  • NTLA -0.15
  • BXC 0.06
  • Stochastic Oscillator
  • NTLA 1.35
  • BXC 17.41

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

About BXC Bluelinx Holdings Inc.

BlueLinx Holdings Inc is engaged in the wholesale distribution of residential and commercial building products. Its business products are split into two categories: Structural products include items such as lumber, plywood, oriented strand board, rebar, and remesh and Specialty products include items such as engineered wood, siding, millwork, outdoor living, specialty lumber and panels, and industrial products. The company's operations are carried out throughout the United States.

Share on Social Networks: